High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania – A prospective cohort study

Autoři: Rahel E. Bircher aff001;  Alex J. Ntamatungiro aff001;  Tracy R. Glass aff002;  Dorcas Mnzava aff001;  Amina Nyuri aff001;  Herry Mapesi aff001;  Daniel H. Paris aff002;  Manuel Battegay aff003;  Thomas Klimkait aff004;  Maja Weisser aff001
Působiště autorů: Ifakara Health Institute, Ifakara, Tanzania aff001;  Swiss Tropical and Public Health Institute, Basel, Switzerland aff002;  University of Basel, Basel, Switzerland aff003;  Molecular Virology, Department Biomedicine Petersplatz, University of Basel, Basel, Switzerland aff004;  St. Francis Referral Hospital, Ifakara, Tanzania aff005;  Departments of Medicine and Clinical Research, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland aff006
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0227600



Poor adherence to antiretroviral drugs and viral resistance are the main drivers of treatment failure in HIV-infected patients. In sub-Saharan Africa, avoidance of treatment failure on second-line protease inhibitor therapy is critical as treatment options are limited.


In the prospective observational study of the Kilombero & Ulanga Antiretroviral Cohort in rural Tanzania, we assessed virologic failure (viral load ≥1,000 copies/mL) and drug resistance mutations in bio-banked plasma samples 6–12 months after initiation of a protease inhibitor-based treatment regimen. Additionally, viral load was measured before start of protease inhibitor, a second time between 1–5 years after start, and at suspected treatment failure in patients with available bio-banked samples. We performed resistance testing if viral load was ≥1000 copies/ml. Risk factors for virologic failure were analyzed using logistic regression.


In total, 252 patients were included; of those 56% were female and 21% children. Virologic failure occurred 6–12 months after the start of a protease inhibitor in 26/199 (13.1%) of adults and 7/53 of children (13.2%). The prevalence of virologic failure did not change over time. Nucleoside reverse transcriptase inhibitors drug resistance mutation testing performed at 6–12 months showed a positive signal in only 9/16 adults. No cases of resistance mutations for protease inhibitors were seen at this time. In samples taken between 1–5 years protease inhibitor resistance was demonstrated in 2/7 adults. In adult samples before protease inhibitor start, resistance to nucleoside reverse transcriptase inhibitors was detected in 30/41, and to non-nucleoside reverse-transcriptase inhibitors in 35/41 patients. In 15/16 pediatric samples, resistance to both drug classes but not for protease inhibitors was present.


Our study confirms high early failure rates in adults and children treated with protease inhibitors, even in the absence of protease inhibitors resistance mutations, suggesting an urgent need for adherence support in this setting.

Klíčová slova:

Antimicrobial resistance – Antiretroviral therapy – Drug therapy – HIV – Protease inhibitor therapy – Protease inhibitors – Tanzania – Viral load


1. Estimates A. Country factsheets UNITED REPUBLIC OF TANZANIA | 2018 HIV and AIDS Estimates Adults and children living with Country factsheets UNITED REPUBLIC OF TANZANIA | 2018 HIV testing and treatment cascade People living with HIV Coverage of adults and children. 2018;1–7.

2. UNAIDS data 2018. https://www.unaids.org/en/resources/documents/2018/unaids-data-2018


4. Hawkins C, Ulenga N, Liu E, Aboud S, Mugusi F, Chalamilla G, et al. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. J Antimicrob Chemother. 2016;71(7):1966–74. doi: 10.1093/jac/dkw051 27076106

5. Ntamatungiro AJ, Muri L, Glass TR, Erb S, Battegay M, Furrer H, et al. Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. J Antimicrob Chemother. 2017;72(7):2069–74. doi: 10.1093/jac/dkx095 28387865

6. Lejone TI, Ringera I, Cheleboi M, Wagner S, Muhairwe J, Klimkait T, et al. The treatment cascade in children with unsuppressed viral load—a reality check in rural Lesotho, Southern Africa. JAIDS J Acquir Immune Defic Syndr [Internet]. 2017;77(3):1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29189416%0Ahttp://Insights.ovid.com/crossref?an=00126334-900000000-96796

7. Muri L, Gamell A, Ntamatungiro AJ, Glass TR, Luwanda LB, Battegay M, et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: An emerging public health concern. Aids. 2017;31(1):61–70. doi: 10.1097/QAD.0000000000001273 27677163

8. Boyd M. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND. Lancet [Internet]. 2013;381(9883):2091–9. Available from: doi: 10.1016/S0140-6736(13)61164-2 23769235

9. Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012;7(3):3–7.

10. Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, et al. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. 2017; doi: 10.1371/journal.pone.0178942 28582463

11. Letang E, Kalinjuma AV, Glass TR, Gamell A, Mapesi H, Sikalengo G, et al. Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO)—A prospective HIV cohort in rural Tanzania. Swiss Med Wkly. 2017;147(July):1–9.

12. Vanobberghen F, Letang E, Gamell A, Mnzava DK, Faini D, Luwanda LB, et al. A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. PLoS One. 2017;12(7):1–17.

13. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015;10(2):1–12.

14. Masimba PJ, Kituma E, Klimkait T, Horvath E, Stoeckle M, Hatz C, et al. Prevalence of Drug-Resistance Mutations and HIV-1 Subtypes in a HIV-1 Infected COHORT in rural Tanzania. AIDS Res Hum Retroviruses [Internet]. 2013;29(9):130627192948006. Available from: http://online.liebertpub.com/doi/abs/10.1089/AID.2011.0367

15. Drug HI V, Database R. Major HIV-1 Drug Resistance Mutations. 2015;3–4. Available from: http://hivdb.stanford.edu/pages/drugSummaries.html

16. Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, et al. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016;214(6):873–83. doi: 10.1093/infdis/jiw219 27402780

17. Murphy RA, Sunpath H, Castilla C, Ebrahim S, Court R, Nguyen H, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr JAIDS [Internet]. 2012;61(2):158–63. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3767995/ doi: 10.1097/QAI.0b013e3182615ad1 22692090

18. Fox MP, Berhanu R, Steegen K, Firnhaber C, Ive P, Spencer D, et al. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Heal. 2016;21(9):1131–7.

19. Rawizza HE, Chaplin B, Meloni ST, Darin KM, Olaitan O, Scarsi KK, et al. Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in Nigeria. PLoS One. 2013;8(9):1–8.

20. Schlatter AF, Deathe AR, Vreeman RC. The need for pediatric formulations to treat children with HIV. AIDS Res Treat. 2016;2016.

21. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008;8(December 2006):1–8. doi: 10.1186/1471-2334-8-1

22. van Oosterhout JJG, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Heal [Internet]. 2009;14(8):856–61. Available from: http://doi.wiley.com/10.1111/j.1365-3156.2009.02309.x

23. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Therapy Outcome. 2013;18(9):1378–85.

24. Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, et al. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis. 2018;18(1):47–57. doi: 10.1016/S1473-3099(17)30630-8 29108797

25. Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa. N Engl J Med [Internet]. 2014;371(3):234–47. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1311274 25014688

26. Siedner MJ, Bwana MB, Moosa M-YS, Paul M, Pillay S, McCluskey S, et al. The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates. HIV Clin Trials [Internet]. 2017;4336:1–7. Available from: https://www.tandfonline.com/doi/full/10.1080/15284336.2017.1349028

27. Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslen M, Bjorkman P. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS One. 2017;12(7):1–15.

28. S.M M, Y B, N M, J.E H, J.N M, P.W H, et al. Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure. J Acquir Immune Defic Syndr [Internet]. 2017;76(2):183–7. Available from: http://journals.lww.com/jaids/pages/default.aspx%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&NEWS=N&AN=616899142 doi: 10.1097/QAI.0000000000001479 28628529

29. Labhardt ND, Bader J, Lejone TI, Ringera I, Hobbins MA, Fritz C, et al. Should viral load thresholds be lowered? Medicine (Baltimore) [Internet]. 2016;95(28):e3985. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00005792-201607120-00011

30. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 2017;17(1):1–11. doi: 10.1186/s12879-016-2122-x

Článek vyšel v časopise


2020 Číslo 1
Nejčtenější tento týden